Text Size

Gait Evaluation in Haemophiliac Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2009 by Cliniques universitaires Saint-Luc- Université Catholique de Louvain.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
ClinicalTrials.gov Identifier:
NCT00824798
First received: January 16, 2009
Last updated: NA
Last verified: January 2009
History: No changes posted
  Purpose

Joint damage secondary to recurrent haemarthroses and chronic synovitis represents the commonest clinical manifestation of haemophilia. Incapacitating pain, loss of joint stability and mobility, axial deviation, deterioration and decreased function are the most frequent complains in patients with severe haemophilic arthropathy In this context, the purpose of our study is to examine and analyse specific changes in gait in patients suffering from haemophilic arthropathy and determine the impact on health-related quality of life in terms of conceptual components of pain and stiffness, psychosocial stress, disability, and activity limitations as recommended by the International Classification of Function (ICF) recently published by the World Health Organization.


Condition
Hemophilia A
Hemophilia B

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Gait Evaluation in Haemophiliac Patients

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Cliniques universitaires Saint-Luc- Université Catholique de Louvain:

Primary Outcome Measures:
  • evaluate specific changes in gait in patients suffering from haemophilic arthropathy [ Time Frame: 01/2009 ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 200
Study Start Date: January 2009
Estimated Study Completion Date: January 2012
Estimated Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
haemophiliacs A and B
haemophiliacs A and B mild, moderate or severe from 4 to 80 years old, with or without inhibitors.

  Eligibility

Ages Eligible for Study:   4 Years to 80 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

haemophilia A or B, mild, moderate or severe.

Criteria

Inclusion Criteria:

  • haemophilia A or B
  • aged more than 4 years

Exclusion Criteria:

  • impossibility to walk on a treadmill
  • recent joint haemarthrosis or muscle haematoma
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00824798

Contacts
Contact: sebastien lobet sebastien.lobet@uclouvain.be

Locations
Belgium
Cliniques universitaires Saint-Luc Recruiting
Brussels, Belgium, 1200
Contact: sebastien lobet     003227641657     sebastien.lobet@uclouvain.be    
Principal Investigator: sebastien lobet            
Sponsors and Collaborators
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
  More Information

No publications provided

Responsible Party: Cliniques universitaires Saint-Luc, service d'hématologie
ClinicalTrials.gov Identifier: NCT00824798     History of Changes
Other Study ID Numbers: READ-LOBET-02, READ-LOBET-02
Study First Received: January 16, 2009
Last Updated: January 16, 2009
Health Authority: Belgium: Institutional Review Board

Keywords provided by Cliniques universitaires Saint-Luc- Université Catholique de Louvain:
gait
haemophilia
arthropathy

Additional relevant MeSH terms:
Hemophilia B
Hemophilia A
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
 Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Genetic Diseases, X-Linked

ClinicalTrials.gov processed this record on May 21, 2013